AllSquare Wealth Management LLC bought a new position in GlaxoSmithKline PLC (NYSE:GSK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 6,900 shares of the pharmaceutical company’s stock, valued at approximately $280,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. CIBC Asset Management Inc grew its holdings in shares of GlaxoSmithKline PLC by 40.0% in the 3rd quarter. CIBC Asset Management Inc now owns 126,490 shares of the pharmaceutical company’s stock worth $5,119,000 after purchasing an additional 36,110 shares during the last quarter. Sei Investments Co. grew its holdings in shares of GlaxoSmithKline PLC by 60.9% in the 3rd quarter. Sei Investments Co. now owns 336,562 shares of the pharmaceutical company’s stock worth $13,665,000 after purchasing an additional 127,441 shares during the last quarter. Wrapmanager Inc. grew its holdings in shares of GlaxoSmithKline PLC by 26.2% in the 3rd quarter. Wrapmanager Inc. now owns 47,330 shares of the pharmaceutical company’s stock worth $1,922,000 after purchasing an additional 9,831 shares during the last quarter. Stevens First Principles Investment Advisors grew its holdings in shares of GlaxoSmithKline PLC by 4.6% in the 3rd quarter. Stevens First Principles Investment Advisors now owns 40,538 shares of the pharmaceutical company’s stock worth $1,646,000 after purchasing an additional 1,785 shares during the last quarter. Finally, GW Henssler & Associates Ltd. grew its holdings in shares of GlaxoSmithKline PLC by 4.0% in the 3rd quarter. GW Henssler & Associates Ltd. now owns 210,343 shares of the pharmaceutical company’s stock worth $8,540,000 after purchasing an additional 8,057 shares during the last quarter. 9.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down $0.47 during mid-day trading on Monday, hitting $35.30. The stock had a trading volume of 5,960,600 shares, compared to its average volume of 3,424,427. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The company has a market cap of $84,680.00, a PE ratio of 12.52, a PEG ratio of 1.96 and a beta of 1.00. GlaxoSmithKline PLC has a one year low of $35.08 and a one year high of $44.53.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be paid a $0.5037 dividend. The ex-dividend date is Thursday, November 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.71%. GlaxoSmithKline PLC’s dividend payout ratio is 159.20%.

Several research firms have recently weighed in on GSK. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. Finally, TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $44.33.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/13/allsquare-wealth-management-llc-buys-shares-of-6900-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.